Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20–243 CrossMab

Transformation-Associated Changes in Sphingolipid Metabolism Sensitize Cells to Lysosomal Cell Death Induced by Inhibitors of Acid Sphingomyelinase

(2013) Nikolaj H.T. Petersen et al.   CANCER CELL

Antibody Therapeutics in Cancer

(2013) M. X. Sliwkowski et al.   SCIENCE

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

(2012) P. Gupta et al.   BLOOD

Non-Hodgkin lymphoma

(2012) Kate R Shankland et al.   LANCET

Dual targeting strategies with bispecific antibodies

(2012) Roland Kontermann   mAbs

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma

(2011) L. Alinari et al.   BLOOD

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

(2011) G. Niederfellner et al.   BLOOD

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

(2011) W. Schaefer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

(2010) R. Stein et al.   BLOOD

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Combating apoptosis and multidrug resistant cancers by targeting lysosomes

(2010) Line Groth-Pedersen et al.   CANCER LETTERS

A Bispecific Antibody-IFN 2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells

(2010) E. A. Rossi et al.   CANCER RESEARCH

Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells

(2010) A Puissant et al.   LEUKEMIA

Evolution of anti- CD20 monoclonal antibody therapeutics in oncology

(2010) Ezogelin Oflazoglu et al.   mAbs

Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma

(2009) B. Li et al.   BLOOD

Anti-CD20 monoclonal antibodies: historical and future perspectives

(2009) S. H. Lim et al.   HAEMATOLOGICA

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

(2008) M. S. Czuczman et al.   CLINICAL CANCER RESEARCH